Intravenous immunoglobulin therapy in COVID-19-related encephalopathy.
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
09
09
2020
accepted:
19
09
2020
revised:
17
09
2020
pubmed:
9
10
2020
medline:
22
7
2021
entrez:
8
10
2020
Statut:
ppublish
Résumé
To report on efficacy and safety of intravenous immunoglobulin (IVIg) therapy in a case series of patients with COVID-19-related encephalopathy. We retrospectively collected data on all patients with COVID-19 hospitalized at two Italian hospitals who developed encephalopathy during disease course and were treated with IVIg. Five patients (two females, mean age 66.8 years) developed encephalopathy after a mean of 12.6 days, since the onset of respiratory/constitutional symptoms related to COVID-19. Four patients suffered severe respiratory distress, three of which required invasive mechanical ventilation. Neurological manifestations included impaired consciousness, agitation, delirium, pyramidal and extrapyramidal signs. EEG demonstrated diffuse slowing in all patients. Brain MRI showed non-specific findings. CSF analysis revealed normal cell count and protein levels. In all subjects, RT-PCR for SARS-CoV-2 in CSF tested negative. IVIg at 0.4 g/kg/die was commenced 29.8 days (mean, range: 19-55 days) after encephalopathy onset, leading to complete electroclinical recovery in all patients, with an initial improvement of neuropsychiatric symptoms observed in 3.4 days (mean, range: 1-10 days). No adverse events related to IVIg were observed. Our preliminary findings suggest that IVIg may represent a safe and effective treatment for COVID-19-associated encephalopathy. Clinical efficacy may be driven by the anti-inflammatory action of IVIg, associated with its anti-cytokine qualities.
Identifiants
pubmed: 33030607
doi: 10.1007/s00415-020-10248-0
pii: 10.1007/s00415-020-10248-0
pmc: PMC7543032
doi:
Substances chimiques
Immunoglobulins, Intravenous
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2671-2675Informations de copyright
© 2020. The Author(s).
Références
Guan WJ, Νi ZY, Hu Y et al (2020) Clinical characteristics of Coronavirus Disease 2019 in China. N Engl J Med 382(18):1708–1720
doi: 10.1056/NEJMoa2002032
Al-Ani F, Chehade S, Lazo-Langner A (2020) Thrombosis risk associated with COVID-19 infection. A scoping review. Thromb Res 192:152–160
doi: 10.1016/j.thromres.2020.05.039
Moore JB, June CH (2020) Cytokine release syndrome in severe COVID-19. Science 368(6490):473–474
doi: 10.1126/science.abb8925
Koralnik IJ, Tyler KL (2020) COVID-19: a global threat to the nervous system. Ann Neurol 88(1):1–11
doi: 10.1002/ana.25807
Pilotto A, Odolini S, Masciocchi S et al (2020) Steroid-responsive encephalitis in coronavirus disease 2019. Ann Neurol. https://doi.org/10.1002/ana.25783
doi: 10.1002/ana.25783
pubmed: 33016374
pmcid: 7436670
Muccioli L, Pensato U, Cani I et al (2020) COVID-19-associated encephalopathy and cytokine-mediated neuroinflammation. Ann Neurol. https://doi.org/10.1002/ana.25855
doi: 10.1002/ana.25855
pubmed: 32715524
Cani I, Barone V, D’Angelo R et al (2020) Frontal encephalopathy related to hyperinflammation in COVID-19. J Neurol. https://doi.org/10.1007/s00415-020-10057-5
doi: 10.1007/s00415-020-10057-5
pubmed: 33030607
pmcid: 7543032
Farhadian S, Glick LR, Vogels CBF et al (2020) Acute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID-19. BMC Neurol 20(1):248. https://doi.org/10.1186/s12883-020-01812-2
doi: 10.1186/s12883-020-01812-2
pubmed: 32552792
pmcid: 7301053
Benameur K, Agarwal A, Auld SC et al (2020) Encephalopathy and encephalitis associated with cerebrospinal fluid cytokine alterations and coronavirus disease, Atlanta, Georgia, USA, 2020. Emerg Infect Dis. https://doi.org/10.3201/eid2609.202122
doi: 10.3201/eid2609.202122
pubmed: 32857691
pmcid: 7706962
Beach SR, Praschan NC, Hogan C et al (2020) Delirium in COVID-19: a case series and exploration of potential mechanisms for central nervous system involvement. Gen Hosp Psychiatry 65:47–53
doi: 10.1016/j.genhosppsych.2020.05.008
Pugin D, Vargas MI, Thieffry C et al (2020) COVID-19-related encephalopathy responsive to high doses glucocorticoids. Neurology. https://doi.org/10.1212/WNL.0000000000010354
doi: 10.1212/WNL.0000000000010354
pubmed: 32680950
Dogan L, Kaya D, Sarikaya T et al (2020) Plasmapheresis treatment in COVID-19-related autoimmune meningoencephalitis: case series. Brain Behav Immun 87:155–158
doi: 10.1016/j.bbi.2020.05.022
Cao W, Liu X, Bai T et al (2020) High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis 7(3):102
doi: 10.1093/ofid/ofaa102
Liu X, Cao W, Li T (2020) High-dose intravenous immunoglobulins in the treatment of severe acute viral pneumonia: the known mechanisms and clinical effects. Front Immunol 11:1660. https://doi.org/10.3389/fimmu.2020.01660
doi: 10.3389/fimmu.2020.01660
pubmed: 32760407
pmcid: 7372093
Lünemann JD, Nimmerjahn F, Dalakas MC (2015) Intravenous immunoglobulin in neurology–mode of action and clinical efficacy. Nat Rev Neurol 11(2):80–89
doi: 10.1038/nrneurol.2014.253
Chaumont H, San-Galli A, Martino F et al (2020) Mixed central and peripheral nervous system disorders in severe SARS-CoV-2 infection. J Neurol. https://doi.org/10.1007/s00415-020-09986-y
doi: 10.1007/s00415-020-09986-y
pubmed: 32533322
pmcid: 7292244
Le Guennec L, Devianne J, Jalin L et al (2020) Orbitofrontal involvement in a neuroCOVID-19 patient. Epilepsia. https://doi.org/10.1111/epi.16612
doi: 10.1111/epi.16612
pubmed: 32589794
pmcid: 7361605
Abe Y, Horiuchi A, Miyake M, Kimura S (1994) Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 139:5–19
doi: 10.1111/j.1600-065X.1994.tb00854.x
Sharief MK, Ingram DA, Swash M, Thompson EJ (1999) I.v. Immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barre syndrome. Neurology 52(9):1833–1838
doi: 10.1212/WNL.52.9.1833
Santomasso BD, Park JH, Salloum D et al (2018) Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov 8(8):958–971
doi: 10.1158/2159-8290.CD-17-1319
St-Amour I, Pare I, Alata W et al (2013) Brain bioavailability of human intravenous immunoglobulin and its transport through the murine blood-brain barrier. J Cereb Blood Flow Metab 33(12):1983–1992
doi: 10.1038/jcbfm.2013.160